Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Cognition Therapeutics announced that President and CEO Lisa Ricciardi will participate in a fireside chat at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion, Ms. Ricciardi plans to review the status of the ongoing START study and the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) for dementia with Lewy bodies psychosis.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.